Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q2 2016 · 10-Q
Revenue$413.00K$413.00K−89.8% vs Q2 2015 Net Income-$6.02M-$6.02MN/M vs Q2 2015 EPS Diluted-$0.42-$0.42N/M vs Q2 2015 Operating Income-$6,366,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,551,000N/M Margins · derivedOperating margin-1541.4%−1546.3 pt vs Q2 2015
Net margin-1456.7%−1485.5 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 3, 2016 · 34 d after period end